Detalles de la búsqueda
1.
Metabolic tumor volume predicts outcome in patients with advanced stage follicular lymphoma from the RELEVANCE trial.
Ann Oncol
; 35(1): 130-137, 2024 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-37898239
2.
The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma.
Ann Oncol
; 33(3): 288-298, 2022 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-34921960
3.
Longitudinal study of AMH variations in 122 Adolescents and Young Adults (AYA) and non-AYA lymphoma patients to evaluate the chemo-induced ovarian toxicity to further personalise fertility preservation counselling.
Hum Reprod
; 36(10): 2743-2752, 2021 09 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-34417822
4.
Lenalidomide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective 'proof of concept' phase II study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA).
Ann Oncol
; 30(4): 621-628, 2019 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30698644
5.
FDG-PET-driven consolidation strategy in diffuse large B-cell lymphoma: final results of a randomized phase 2 study.
Blood
; 130(11): 1315-1326, 2017 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-28701367
6.
Risk factors and a prognostic score for survival after autologous stem-cell transplantation for relapsed or refractory Hodgkin lymphoma.
Ann Oncol
; 28(6): 1352-1358, 2017 Jun 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28327958
7.
Phase II study of copanlisib, a PI3K inhibitor, in relapsed or refractory, indolent or aggressive lymphoma.
Ann Oncol
; 28(9): 2169-2178, 2017 Sep 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28633365
8.
International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).
Ann Oncol
; 28(7): 1436-1447, 2017 Jul 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28379322
9.
Radioimmunotherapy ((90) Y-Ibritumomab Tiuxetan) for Posttransplant Lymphoproliferative Disorders After Prior Exposure to Rituximab.
Am J Transplant
; 15(7): 1976-81, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25868706
10.
International prognostic index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial.
Am J Transplant
; 15(4): 1091-100, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25736912
11.
Utility of ¹8fluoro-deoxyglucose positron emission tomography for prognosis and response assessments in a phase 2 study of romidepsin in patients with relapsed or refractory peripheral T-cell lymphoma.
Ann Oncol
; 26(4): 774-779, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25605745
12.
Primary CNS posttransplant lymphoproliferative disease (PTLD): an international report of 84 cases in the modern era.
Am J Transplant
; 13(6): 1512-22, 2013 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-23721553
13.
Phase III study of ACVBP versus ACVBP plus rituximab for patients with localized low-risk diffuse large B-cell lymphoma (LNH03-1B).
Ann Oncol
; 24(4): 1032-7, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23235801
14.
Rituximab induction immunotherapy for first-line low-tumor-burden follicular lymphoma: survival analyses with 7-year follow-up.
Ann Oncol
; 23(9): 2380-2385, 2012 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-22782332
15.
A 4-weekly course of rituximab is safe and improves tumor control for patients with minimal residual disease persisting 3 months after autologous hematopoietic stem-cell transplantation: results of a prospective multicenter phase II study in patients with follicular lymphoma.
Ann Oncol
; 23(10): 2687-2695, 2012 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-22767588
16.
Inhibition of Hedgehog signaling for the treatment of lymphoma and CLL: a phase II study from the LYSA.
Ann Oncol
; 27(7): 1349-50, 2016 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-27002105
17.
FDG-PET in the assessment of patients with follicular lymphoma treated by ibritumomab tiuxetan Y 90: multicentric study.
Ann Oncol
; 21(9): 1877-1883, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20147744
18.
Results of a phase I/II study of ocrelizumab, a fully humanized anti-CD20 mAb, in patients with relapsed/refractory follicular lymphoma.
Ann Oncol
; 21(9): 1870-1876, 2010 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-20157180
19.
Antibody-drug conjugates for previously treated aggressive lymphomas: focus on polatuzumab vedotin.
Expert Rev Clin Pharmacol
; 13(10): 1073-1083, 2020 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-32985934
20.
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
Ann Oncol
; 19(2): 247-53, 2008 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-17906297